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Background: Cost-Effective Analysis (CEA) from recent RCTs comparing TAVR and SAVR are useful but may not represent outcomes expected in a 
broad clinical practice. Markov decision analytic modeling may provide useful insights in this setting
methods: We developed a Markov decision analytic lifetime model with Monte Carlo simulations in cohorts at “high risk” for SAVR. We informed 
the TAVR arm of our model using data from a recent meta-analysis of 16 registries using VARC outcomes (Genereux JACC 2012), and 4 contemporary 
surgical registries. Utilities for TAVR and SAVR were used from the Partner A data.
results: Probabilistic sensitivity analysis using Monte Carlo simulation of 10,000 samples estimated that TAVR was associated with a lifetime cost 
of $81,548 ± $1,240 and an effectiveness of 3.54 ± 0.07 QALYS. Patients undergoing SAVR accumulated $99,641± $3,126 and 3.45 ± 0.08 QALYS. 
TAVR was found to be a dominant strategy. The model was sensitive to variations in the probability of new dialysis in SAVR patients. If this rate fell 
below 3.3% in the SAVR arm, SAVR provided a greater net monetary benefit. Our estimated value with perfect information (EVPI) would save $2,919 
and gain 0.2 QALYS per patient by using TAVR over SAVR.
discussion: In our decision model, TAVR was the dominant strategy over SAVR, though with a significant reduction in cost and small gain in QALYs. 
Prospective cost-analysis of these patients outside the setting of clinical trials will be beneficial for further evaluation of these therapies.
